25 studies found for:    Open Studies | copd | United States, North Carolina
Show Display Options
Rank Status Study
1 Recruiting Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.
Conditions: COPD;   Chronic Obstructive Pulmonary Disease;   Moderate to Very Severe COPD
Interventions: Drug: Aclidinium Bromide;   Drug: Placebo
2 Not yet recruiting Efficacy and Safety Study of QVA149 in COPD Patients
Condition: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: QVA149;   Drug: Umeclidinium/vilanterol;   Drug: Placebo (umeclidinium/vilanterol);   Drug: Placebo (QVA149)
3 Not yet recruiting Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in COPD Patients
Condition: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: QVA149;   Drug: Umeclidinium/vilanterol;   Drug: Placebo (umeclidinium/vilanterol );   Drug: Placebo (QVA149)
4 Recruiting A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects
Condition: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: Arformoterol tartrate inhalation solution;   Drug: Tiotropium
5 Recruiting Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)
Condition: COPD
Interventions: Drug: BGF MDI 320/14.4/9.6 μg;   Drug: GFF MDI 14.4/9.6 μg;   Drug: BGF MDI 160/14.4/9.6 μg;   Drug: BFF MDI 320/9.6 μg
6 Recruiting Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History
Condition: Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Interventions: Drug: Benralizumab Arm A;   Drug: Benralizumab Arm B;   Drug: Placebo
7 Recruiting Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History
Condition: Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Interventions: Drug: Benralizumab Arm A;   Drug: Benralizumab Arm B;   Drug: Benralizumab Arm C;   Drug: Placebo
8 Recruiting Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Condition: COPD
Interventions: Drug: BGF MDI (PT010) 320/14.4/9.6 μg;   Drug: GFF MDI (PT003) 14.4/9.6 μg;   Drug: BFF MDI (PT009) 320/9.6 μg
9 Recruiting A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)
Condition: COPD
Interventions: Drug: BGF MDI 320/14.4/9.6 μg;   Drug: GFF MDI (PT003) 14.4/9.6 μg;   Drug: BFF MDI (PT009) 320/9.6 μg;   Drug: Symbicort® Turbuhaler® (TBH) Inhalation Powder
10 Recruiting Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD
Condition: COPD
Interventions: Drug: GFF MDI (PT003);   Drug: FF MDI (PT005);   Drug: GP MDI (PT001);   Drug: Placebo MDI
11 Recruiting Crossover Study to Assess the Efficacy of PT003 With and Without a Valved Holding Chamber in Subjects With Moderate to Severe COPD
Condition: COPD
Interventions: Device: GFF MDI (PT003) with Aerochamber;   Device: GFF MDI (PT003) without Aerochamber
12 Recruiting A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: fluticasone furoate (FF);   Drug: vilanterol (VI);   Drug: umeclidinium bromide (UMEC)
13 Recruiting A Study to Evaluate Safety and Efficacy of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Condition: COPD, Chronic Obstructive Pulmonary Disease
Interventions: Drug: Lebrikizumab;   Drug: Placebo
14 Recruiting Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
Conditions: Emphysema;   Chronic Obstructive Pulmonary Disease (COPD);   Cystic Fibrosis;   Pulmonary Fibrosis;   Bronchiectasis;   Sarcoidosis;   Pulmonary Hypertension;   Alpha-1 Antitrypsin Deficiency
Interventions: Procedure: Transplantation of lungs obtained from Non-Heart-Beating Donors (NHBDs) after ex-vivo perfusion w/ STEEN Solution™;   Device: STEEN Solution™
15 Recruiting Phase IV O2 Consumption Study in COPD Patients
Condition: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: Budesonide 160 mcg and formoterol fumarate dehydrate 4.5 mcg Inhalation aerosol;   Drug: Matching Placebo pMDI 160/4.5 μg
16 Recruiting A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251
Condition: Chronic Obstructive Pulmonary Disease, COPD
Interventions: Drug: QBW251;   Drug: Placebo
17 Recruiting Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: olodaterol;   Drug: tiotropium
18 Recruiting Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Batefenterol + Fluticasone Furoate;   Drug: Placebo;   Drug: Albuterol
19 Unknown  Evaluation of FeNO During and Following Acute COPD Exacerbation
Condition: Chronic Obstructive Pulmonary Disease
Intervention: Device: NIOX MINO®
20 Recruiting Safety and Efficacy of Adipose Derived Stem Cells for Chronic Obstructive Pulmonary Disease
Condition: Chronic Obstructive Pulmonary Disease
Intervention: Drug: Adipose Derived Stem Cell (ADSC) Therapy

   Previous Page Studies Shown (1-20) Next Page (21-25) Show next page of results    Last Page
Indicates status has not been verified in more than two years